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Erythrocytes, hemoglobin and iron are present in advanced atherosclerotic lesions. We 
have investigated whether red cell infiltration of atheromatous lesions promotes the later 
stages of atherogenesis. 
We find that oxidation of ferro (FeII) hemoglobin in ruptured advanced lesions 
intensively occurs generating ferri (FeIII) hemoglobin and via more extensive oxidation 
(FeIII/FeIV=O) ferrylhemoglobin. Protein oxidation marker, dityrosine, is accumulated in 
complicated lesions accompanied by the formation of crosslinked hemoglobin a hallmark of 
ferrylhemoglobin. Exposure of normal red cells to lipids derived from atheromatous lesions 
causes hemolysis and oxidation of liberated hemoglobin to ferri- and ferrylhemoglobin. In 
these interactions between hemoglobin and atheroma lipids hemoglobin and heme promote 
further lipid oxidation and subsequently endothelial reactions such as upregulation of heme 
oxygenase-1 or cytotoxicity to endothelium. Oxidative scission of heme leads to release of 
iron and a feed-forward process of iron-driven plaque lipid oxidation. The inhibition of heme 
release from globin by haptoglobin and sequestration of heme by hemopexin suppress 
hemoglobin-mediated oxidation of lipids of atheromatous lesions and attenuate endothelial 
cytotoxicity. 
Interior of advanced atheromatous lesions is a pro-oxidant environment in which 
erythrocytes are lysed, hemoglobin is readily oxidized to ferri- and ferrylhemoglobin, and 
released heme and iron promote further oxidation of lipids. These events amplify the 
endothelial cell cytotoxicity of plaque components. 
Several pathologic conditions are associated with hemolysis, i.e. release of ferro (FeII) 
hemoglobin from red blood cells including atherosclerosis. Oxidation of cell-free hemoglobin 
produces (FeIII) ferrihemoglobin. More extensive oxidation produces (FeIII/FeIV=O) 
ferrylhemoglobin. Both cell-free ferrihemoglobin and ferrylhemoglobin are thought to 
contribute to the pathogenesis of hemolytic disorders including atherosclerosis.  
We revealed that ferrylhemoglobin, but not hemoglobin or ferrihemoglobin, acts as a potent 
proinflammatory agonist that induces vascular endothelial cells in vitro to rearrange the actin 
cytoskeleton, forming intercellular gaps and disrupting the integrity of the endothelial cell 
monolayer. Furthermore, ferrylhemoglobin induces the expression of proinflammatory genes 
in endothelial cells in vitro, e.g. E-selectin, Icam-1, and Vcam-1, through the activation of the 
nuclear factor B family of transcription factors. This proinflammatory effect, which requires 
actin polymerization, involves the activation of the c-Jun N-terminal kinase and the p38 
mitogen-activated protein kinase signal transduction pathways. When administered to naive 
mice, ferrylhemoglobin induces the recruitment of polymorphonuclear cells, demonstrating 
that it acts as a proinflammatory agonist in vivo. We conclude that oxidized hemoglobin, i.e. 
ferrylhemoglobin, acts as a proinflammatory agonist that targets vascular endothelial cells. 
Interaction of hemoglobin with vasculature is remarkable in malaria. Plasmodium, the 
causative agent of malaria, causes extensive hemolysis, and cerebral malaria claims more than 
1 million lives per year. Therefore we chose a model of malaria to study the interaction of 
hemoglobin with the constituent of vasculature. We hypothesized that carbon monoxide might 
counter the pathogenesis of cerebral malaria, an inflammatory syndrome that can develop in 
the course of malaria infection and lead to neurological disturbances revealed clinically by 
abnormal behavior, impairment of consciousness, seizures and irreversible coma, ultimately 
leading to death. We report that heme oxygenase-1 (encoded by Hmox1) prevents the 
development of experimental cerebral malaria. BALB/c mice infected with Plasmodium 
berghei ANKA upregulated heme oxygenase-1 expression and activity and did not develop 
cerebral malaria. Deletion of Hmox1 and inhibition of heme oxygenase activity increased 
cerebral malaria incidence to 83% and 78%, respectively. Heme oxygenase-1 upregulation 
was lower in infected C57BL/6 compared to BALB/c mice, and all infected C57BL/6 mice 
developed cerebral malaria (100% incidence). Pharmacological induction of heme oxygenase-
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1 and exposure to the end-product of heme oxygenase-1 activity, carbon monoxide, reduced 
cerebral malaria incidence in C57BL/6 mice to 10% and 0%, respectively. Whereas neither 
heme oxygenase-1 nor carbon monoxide affected parasitemia, both prevented blood-brain 
barrier disruption, brain microvasculature congestion and neuroinflammation, including 
CD8+ T-cell brain sequestration. These effects were mediated by the binding of carbon 
monoxide to hemoglobin, preventing hemoglobin oxidation and the generation of free heme, a 
molecule that triggers cerebral malaria pathogenesis. 
Heme-mediated oxidation of low-density lipoprotein has been implicated in the 
pathogenesis of vascular disorders such as atherosclerosis. We performed investigations to 
test whether hydrophobic fungal siderophores – hexadentate trihydroxamates 
desferricoprogen, desferrichrome, desferrirubin, and desferrichrysin – might suppress heme-
catalyzed LDL oxidation and the toxic effects of heme-treated LDL on vascular endothelium. 
Indeed, two of these – desferricoprogen and desferrichrome – markedly increased the 
resistance of LDL to heme-catalyzed oxidation. In similar dose–response fashion, these 
siderophores also inhibited the generation of LDL products cytotoxic to human vascular 
endothelium. When iron-free fungal siderophores were added to LDL/heme oxidation 
reactions, the product failed to induce heme oxygenase-1, a surrogate marker for the 
noncytocidal effects of oxidized LDL (not in the case of desferrichrysin). Desferricoprogen 
also hindered the ironmediated peroxidation of lipids from human atherosclerotic soft plaques 
in vitro, and was taken up in the gastrointestinal tract of rat. The absorbed siderophore was 
accumulated in the liver and was secreted in its iron-complexed form in the feces and urine. 
The consumption of mold-ripened food products such as aged cheeses and the introduction of 
functional foods and food additives rich in fungal iron chelators in diets may lower the risk of 
cardiovascular diseases. 
Since heme interacts with vascular wall, we wondered if it plays a role in the 
pathogenesis of calcification in atherosclerosis, diabetes, and chronic kidney disease. Human 
aortic smooth muscle cells undergo mineralization in response to elevated levels of inorganic 
phosphate in an active and well-regulated process. This process involves increased activity of 
alkaline phosphatase and increased expression of core binding factor-1, a bone-specific 
transcription factor, with the subsequent induction of osteocalcin. Mounting evidence 
suggests an essential role for the heme oxygenase-1/ferritin system to maintain homeostasis of 
vascular function. We examined whether induction of heme oxygenase-1 and ferritin 
provoked by heme alters mineralization of human aortic smooth muscle cells provoked by 
high phosphate. Upregulation of the heme oxygenase-1/ferritin system inhibited human aortic 
smooth muscle cells calcification and osteoblastic differentiation. Of the products of the 
system induced by heme, only ferritin and, to a lesser extent, biliverdin were responsible for 
the inhibition. Ferritin heavy chain and ceruloplasmin, which both possess ferroxidase 
activity, inhibited calcification; a site-directed mutant of ferritin heavy chain, which lacked 
ferroxidase activity, failed to inhibit calcification. In addition, osteoblastic transformation of 
human aortic smooth muscle cells provoked by elevated phosphate (assessed by upregulation 
of core binding factor -1, osteocalcin, and alkaline phosphatase activity) was diminished by 
ferritin/ferroxidase activity. We conclude that induction of the heme oxygenase-1/ferritin 
system in response to heme prevents phosphate -mediated calcification and osteoblastic 
differentiation of human smooth muscle cells mainly via the ferroxidase activity of ferritin. 
Calcification of intima or media of vascular wall is often associated with calcium 
depletion of bone therefore we examined its remodeling capacity in response to heme stress. It 
has been suggested that mobilization of calcium from bone results in translocation of mineral 
into the vasculature. Bone is an active tissue with constant remodeling capacity. Osteoblast 
development and maturation are under the influence of core binding factor a-1, which induces 
expression of osteoblast specific genes, including alkaline phosphatase, an important enzyme 
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in early osteogenesis, and osteocalcin, a noncollagenous protein deposited within the osteoid. 
We investigated the mechanism by which heme affects human osteoblast activity, which in 
vivo may lead to decreased mineralization, osteopenia, and osteoporosis along with vascular 
calcification. We demonstrated that heme inhibited osteoblast activity and the effect on 
osteoblast is mediated by ferritin and its ferroxidase activity. We confirmed this notion by 
using purified ferritin H-chain and ceruloplasmin, both known to possess ferroxidase activity 
that inhibited calcification, whereas a sitedirected mutant of ferritin H-chain lacking 
ferroxidase activity failed to provide any inhibition. Furthermore, we are reporting that such 
suppression is not restricted to inhibition of calcification, but osteoblast-specific genes such as 
alkaline phosphatase, osteocalcin, and core binding factor a-1 are all downregulated by heme 
induced ferritin in a dose-responsive manner. This study provided evidence that heme 
decreases mineralization and demonstrates that this suppression is provided by heme-induced 
upregulation of ferritin. In addition, we conclude that inhibition of osteoblast activity, 
mineralization, and specific gene expression is attributed to the ferroxidase activity of ferritin. 
 
